Real-World study tracks ninlaro safety in chinese myeloma patients
NCT ID NCT04328662
First seen Jun 27, 2026 · Last updated Jun 27, 2026
Summary
This study looked at the safety of the drug Ninlaro (ixazomib) when used to treat multiple myeloma in everyday medical practice in China. About 482 patients were observed, and researchers recorded any side effects or dose changes. The goal was to gather real-world safety information, not to test a new treatment.
This is an AI summary of the original study and may miss details. Read our disclaimer.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for MULTIPLE MYELOMA are added.
By submitting, you agree to our Terms of use
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
Contacts and locations
Locations
-
Affiliated Hospital of Jining Medical College
Jining, Shandong, 272007, China
-
Anhui Cancer Hospital
Hefei, Anhui, 230031, China
-
Beijing Chao-yang Hospital,Capital Medical University
Beijing, Beijing Municipality, 100020, China
-
Beijing Chao-yang Hospital,Capital Medical University(Shijingshan)
Beijing, Beijing Municipality, 100043, China
-
Beijing Jishuitan Hospital
Beijing, Beijing Municipality, 100035, China
-
Datong Third People's Hospital
Datong, Shanxi, 037046, China
-
Hainan General Hospital
Haikou, Hainan, 570311, China
-
Harbin Medical University Cancer Hospital
Harbin, Heilongjiang, 150081, China
-
Henan Cancer Hospital
Zhengzhou, Henan, 450003, China
-
Peking Union Medical College Hospital
Beijing, Beijing Municipality, 100730, China
-
Peking University First Hospital
Beijing, Beijing Municipality, 100034, China
-
Peking University Third Hospital
Beijing, Beijing Municipality, 100191, China
-
Shanxi Provincial People's Hospital
Taiyuan, Shanxi, 030012, China
-
Shaoxing People's Hospital
Shaoxing, Zhejiang, 312099, China
-
Soochow Hongci Blood Disease Hospital
Suzhou, Jiangsu, 215100, China
-
Sun Yat-Sen Memorial Hospital
Guangzhou, Guangdong, 510120, China
-
Tai'an Central Hospital
Tai’an, Shandong, 271099, China
-
Taizhou First People's Hospital
Taizhou, Zhejiang, 318020, China
-
The First Affiliated Hospital of Dalian Medical University
Dalian, Liaoning, 116011, China
-
The First Affiliated Hospital of Soochow University
Suzhou, Jiangsu, 215006, China
-
The First Bethune Hospital of Jilin University
Changchun, Jilin, 130021, China
-
The First Hospital of China Medical University
Shenyang, Liaoning, 110001, China
-
The Third Affiliated Hospital of Sun Yat-sen University
Guangzhou, Guangdong, 510630, China
-
Tianjin Medical University General Hospital
Tianjin, Tianjin Municipality, 300052, China
-
West China Hospital, Sichuan University
Chengdu, Sichuan, 610041, China
-
Wuxi People's Hospital
Wuxi, Jiangsu, 214023, China
-
Zhabei Central Hospital, Jing'an District, Shanghai
Shanghai, Shanghai Municipality, 200070, China
-
Zhujiang Hospital, Southern Medical University
Guangzhou, Guangdong, 510280, China
More trials for these conditions
Other studies related to the condition(s) this trial covers.
- Could muscle loss predict blood cancer outcomes?
- Can a Triple-Action antibody deepen remissions in myeloma?
- Can a Low-Dose antifungal shield vulnerable patients from deadly fungal infections?
- Can a gentler chemo prep make stem cell transplants safer for blood cancer patients?
- Talking about the end: could guided conversations reduce futile cancer treatments?
- A guided path back to work after blood cancer: a trial tests the impact